Topic: How To Invest

Acquisition just one area of growth for Johnson & Johnson

Acquisition just one area of growth for Johnson & Johnson

Pat McKeough responds to many personal questions about stock market investments and other topics on investment and the economy from the members of his Inner Circle. Every week, his comments and recommendations on the most intriguing questions of the past week go out to all Inner Circle members. And each week, we offer you one of the highlights from these Q&A sessions. While we reserve our buy-hold-sell advice for Inner Circle members, these excerpts provide a great deal of information and analysis on stocks we’ve covered for members of Pat’s Inner Circle.

This week, we had a question from an Inner Circle member on one of the world’s best known companies, Johnson & Johnson. The company continues to grow, acquiring a Swiss medical device maker in the past year, and it is working on new treatments to strengthen its drug pipeline. Pat takes a detailed look at the company’s financial strength and assesses its prospects for growth in the coming year.

Q: Pat: What do you think of the prospects for Johnson & Johnson? Thank you.

A: Johnson & Johnson, (symbol JNJ on New York www.jnj.com) has three divisions: Consumer (including products for babies, skin care, oral care and wound care), Pharmaceutical (which makes anti-infective, antipsychotic, contraceptive, dermatological and gastrointestinal drugs) and Medical Devices & Diagnostics (which sells equipment for circulatory disease management and orthopedic joint reconstruction).

In June 2012, Johnson & Johnson paid $20.2 billion—$19.7 billion in cash plus $500 million in stock—for Switzerland-based Synthes. However, this company held cash of $2.7 billion, so the actual cost was $17.5 billion.

Synthes looks like a good fit with Johnson & Johnson: the company makes a wide variety of medical devices and surgical tools, including implants that help bones heal. To win regulatory approval for the purchase, Johnson & Johnson agreed to sell Synthes’s trauma division, which makes plates and screws for broken bones.

If you disregard costs to integrate Synthes and other unusual items, Johnson & Johnson would have earned $3.4 billion in the three months ended December 31, 2012. That’s up 7.9% from $3.1 billion a year earlier. Earnings per share rose 5.3%, to $1.19 from $1.13, on more shares outstanding.

Revenue rose 8.0%, to $17.6 billion from $16.3 billion. Overseas markets supplied 58% of Johnson & Johnson’s fourth-quarter revenue, and the high value of the U.S. dollar cut the company’s sales growth by 1.3%. That was offset by Synthes’s contribution, recently launched drugs and stronger demand for consumer products like Listerine mouthwash and Neutrogena skin cream.

New treatments for HIV, schizophrenia and cancer expected to firm up drug pipeline

Because Johnson & Johnson mostly paid cash for Synthes, it didn’t have to borrow to complete this purchase. As a result, its long-term debt of $11.5 billion remains low, at 5.4% of its market cap. The company ended 2012 with cash and investments of $21.1 billion, or $7.74 a share. However, the acquisition pushed up its goodwill by 39.0%, to $22.4 billion, or 10.5% of its market cap.

The company’s Consumer division is the steadiest part of its business, but it is still suffering from the effects of a number of product recalls. That has forced Johnson & Johnson to take a number of steps to regain consumers’ trust, including upgrading facilities and bringing in new testing procedures.

In addition, the company continues to work on strengthening its drug pipeline, which has been a weak point. It’s now working on several promising new treatments, including Prezista for HIV, Xarelto for stroke prevention, Invega for schizophrenia and Zytiga for prostate cancer. Johnson & Johnson spends around 11% of its sales on research.

The new U.S. health care law imposes fees on companies that supply drugs to U.S. government programs. In 2012, these fees added $115 million to Johnson & Johnson’s costs.

Even with these added costs, Johnson & Johnson’s earnings per share should rise 6.1% in 2013, to $5.41 from $5.10 in 2012. The stock trades at 15.2 times that estimate. The $2.44-a-share dividend yields 3.0%.

In the Inner Circle Q&A, Pat looks at Johnson & Johnson’s financial outlook for the coming year and examines whether progress with its international businesses can offset the impact of a sluggish U.S. economy. He concludes with his clear buy-hold-sell advice on the stock.

(Note: If you are a current member of the Inner Circle, please click here to view Pat’s recommendation. Be sure to log in first.)

COMMENTS PLEASE—Share your investment experience and opinions with fellow TSINetwork.ca members

Many U.S. multinationals offer investors a relatively safe way to invest in international markets with their vast overseas sales. Do you believe these firms have unlimited growth ahead in developing nations, or do you think they will run into resistance from growing local competition and governments anxious to promote their own national interests? Let us know what you think.

Comments

Tell Us What YOU Think

You must be logged in to post a comment.

Please be respectful with your comments and help us keep this an area that everyone can enjoy. If you believe a comment is abusive or otherwise violates our Terms of Use, please click here to report it to the administrator.